Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Does AERS Mean? FDA Takes A Close Look At Spontaneous Reporting

Executive Summary

Amid a flurry of recent drug safety initiatives, FDA is not losing sight of the importance of spontaneous adverse event reporting. In fact, the agency is taking steps to evaluate and improve its passive surveillance system, which it expects to remain the cornerstone of its drug safety oversight

You may also be interested in...



FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing

Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market

FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing

Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market

Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss

Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects

Related Content

UsernamePublicRestriction

Register

PS049301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel